What is HC Wainwright’s Forecast for AGIO Q4 Earnings?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Stock analysts at HC Wainwright issued their Q4 2025 earnings per share (EPS) estimates for Agios Pharmaceuticals in a report issued on Monday, February 24th. HC Wainwright analyst E. Bodnar forecasts that the biopharmaceutical company will post earnings of ($1.42) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $58.00 target price on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%.

Several other equities analysts have also recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Royal Bank of Canada boosted their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Scotiabank upped their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Finally, StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Stock Up 0.7 %

Shares of NASDAQ AGIO opened at $35.47 on Tuesday. The stock has a market cap of $2.03 billion, a P/E ratio of 3.13 and a beta of 0.88. The firm’s 50-day simple moving average is $34.14 and its 200 day simple moving average is $42.98. Agios Pharmaceuticals has a fifty-two week low of $27.14 and a fifty-two week high of $62.58.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of AGIO. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 363 shares during the period. Summit Investment Advisors Inc. lifted its position in shares of Agios Pharmaceuticals by 7.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company’s stock valued at $194,000 after acquiring an additional 394 shares in the last quarter. Federated Hermes Inc. boosted its stake in Agios Pharmaceuticals by 4.4% in the 4th quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company’s stock worth $450,000 after purchasing an additional 582 shares during the period. KBC Group NV grew its position in Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 611 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Agios Pharmaceuticals by 6.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock valued at $539,000 after purchasing an additional 688 shares during the period.

Insider Activity

In other news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares of the company’s stock, valued at $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.